奥妥珠单抗对大关节受累类风湿关节炎患者的疗效:OHZORA与NATSUZORA试验事后分析
该事后分析比较奥妥珠单抗30mg每4周治疗52周在类风湿关节炎(RA)伴或不伴大关节受累(LJI)患者中的疗效。LJI组基线疾病活动度显著更高,但自治疗第3天起差异消失;两组改良Sharp评分变化相似。结论认为无论有无LJI,奥妥珠单抗均可能改善疾病活动度和身体功能障碍并防止关节破坏。
要点
- LJI组基线CDAI显著高于无LJI组,但治疗第3天起及后续多数评估无差异。
- 伴LJI患者血IL-6和MMP-3水平在治疗期间持续下降。
- OHZORA试验中两组第24周改良Total Sharp评分变化相似。
核心结论
- 奥妥珠单抗可能改善疾病活动度和身体功能障碍并防止关节破坏,无论是否存在大关节受累,对LJI患者也是合理治疗选择。
研究设计与样本
- 对OHZORA(联用甲氨蝶呤)和NATSUZORA(不联用甲氨蝶呤)随机试验中接受奥妥珠单抗30mg每4周治疗52周的日本RA患者进行事后分析。
- 按LJI(肩、肘、膝或踝肿胀)分组,检查疾病活动度、身体功能障碍、血炎症标志物水平和关节破坏进展。
- OHZORA试验纳入152例(111例伴LJI,41例不伴LJI);NATSUZORA试验纳入94例(72例伴LJI,22例不伴LJI)。
主要发现
- 两项试验完成率在患者组间无显著差异。
- 伴LJI患者基线CDAI评分显著高于不伴LJI患者,但该差异在奥妥珠单抗治疗第3天及后续多数评估时已不存在。
- 患者报告/医生报告结局和HAQ观察到类似趋势。
- 伴LJI患者血IL-6和MMP-3水平在治疗期间持续下降。
- OHZORA试验中第24周改良Total Sharp评分变化在组间相似。
临床怎么用
- 奥妥珠单抗30mg每4周治疗52周可能作为伴大关节受累RA患者的合理治疗选择。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To compare the efficacy of ozoralizumab in patients with rheumatoid arthritis (RA), with or without large joint involvement (LJI). METHODS: A post hoc analysis was conducted for Japanese patients with RA who received ozoralizumab 30 mg every 4 weeks for 52 weeks in the previous OHZORA (with concomitant methotrexate) and NATSUZORA (without concomitant methotrexate) randomised trials. Patients were subgrouped by LJI, defined as the presence of swelling in the shoulder, elbow, knee or ankle. Disease activity, physical dysfunction, blood inflammatory marker levels and progression of joint destruction during treatment were examined. RESULTS: The numbers of patients included were 152 for the OHZORA trial (111 with LJI, 41 without LJI) and 94 for the NATSUZORA trial (72 with LJI, 22 without LJI). The completion rates of both trials did not differ significantly between the patient groups. Baseline Clinical Disease Activity Index scores were significantly higher in patients with LJI than in those without LJI, but this difference was not present as early as day 3 of ozoralizumab treatment and at most subsequent assessments. A similar trend was observed for patient-reported/physician-reported outcomes and Health Assessment Questionnaire. Blood interleukin-6 and matrix metalloproteinase-3 levels in patients with LJI continuously decreased during treatment. Changes in modified Total Sharp Score at week 24 were similar between the groups in the OHZORA trial. CONCLUSION: Ozoralizumab has the potential to improve disease activity and physical dysfunction and prevent joint destruction in patients, regardless of the presence of LJI, and is a reasonable treatment option, even for patients with LJI. TRIAL REGISTRATION NUMBER: jRCT2080223971 and jRCT2080223973.
引用
- Ebina K, Okamoto S, Kyuuma M, et al. Efficacy of ozoralizumab in rheumatoid arthritis patients with large joint involvement: a post hoc analysis of OHZORA and NATSUZORA trials. RMD Open. 2025. PMID: 41381211. doi:10.1136/rmdopen-2025-006218
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。